

## REMARKS

By this amendment, the abstract of the disclosure has been amended to form a single paragraph as instructed by the Examiner.

Claim 2 has been withdrawn as a non-elected claim.

Claims 1-10 were rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicants regard as their invention. Claim 2 has been withdrawn.

By this amendment claims 1, 5, and 6 have been amended to correct the ambiguity noted by the Examiner. Moreover, these claims have been amended to more clearly set forth the invention. If there is a further problem with this amendment, applicants attorney would appreciate a phone call.

Claims 1, 3, 4, 6-8, and 10 are rejected under 35 USC § 102(b) as being anticipated by Fujiyama et al. (JP 08-113622). Claims 1 and 4-10 were rejected under 35 U.S.C. § 103(a) as being unpatentable over Leclerc et al. (US Pat. No. 6,630,254) in view of Fujiyama et al. (JP 08-113622).

By this amendment, independent claims 1, and 5 have been changed to clearly indicate that an azo group is not present in the conjugated group X. In formula III of Fujiyama et al., an azo group is required. None of the examples in the present application include an azo group. The azo group in Fujiyama et al. has a number of difficulties that are not present in the present invention. These difficulties include low luminance efficiency and poor operational stability. Clearly, the present invention, provides advantages over Fujiyama et al. that were not recognized by Fujiyama et al. If one were to substitute carbazole group of Leclerc et al. into formula III of Fujiyama et al., there would still be an azo group and the above noted disadvantages would still be present. Moreover, there are numerous examples set forth in Fujiyama et al. which are not related to the present invention but out of this list of examples, one would have to realize that only one of these examples should be substituted with the Leclerc et al. compound and the azo group would have to be eliminated in order to provide the present invention. This is unreasonable since Fujiyama et al. require an azo group. There is no motivation to provide this substitution in either reference and to remove the azo group.


Claim 6 has been amended to indicate that the material in question is solution coated. Solution coating provides a simple way to coat a layer without requiring complex equipment. Fujiyama et al. clearly indicates that there compound should be vacuum deposited. Solution coating facilitates large area coating as opposed to vacuum deposition. The polymer set forth in claim 6 of the present invention is advantageous since it can be solution coated. This feature is not suggested or disclosed by the cited art.

It is believed that claims 1, 5 and 6 set forth unobvious subject matter and should be allowable. The remaining claims are in dependent format and each depend on one of these independent claims. They also should be allowable.

It is believed that these changes now make the claims clear and definite and, if there are any problems with these changes, Applicants' attorney would appreciate a telephone call.

In view of the foregoing, it is believed none of the references, taken singly or in combination, disclose the claimed invention. Accordingly, this application is believed to be in condition for allowance, the notice of which is respectfully requested.

Respectfully submitted,



---

Attorney for Applicant(s)  
Registration No. 22,363

Raymond L. Owens/djw  
Rochester, NY 14650  
Telephone: 585-477-4653  
Facsimile: 585-477-4646

If the Examiner is unable to reach the Applicant(s) Attorney at the telephone number provided, the Examiner is requested to communicate with Eastman Kodak Company Patent Operations at (585) 477-4656.

**Amendments to the Drawings:**

Replacement sheets for FIGS. 1-4 are enclosed which formalize the drawings that were submitted with the application. No other changes have been made. Formal drawings are submitted herewith under separate Letter to the Official Draftsperson. Approval by the Examiner is respectfully requested.